Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

Authors

Rocco Serrao
Ulrike Blume‐Peytavi (ORCID: https://orcid.org/0000-0003-3528-3752)
Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
Adriána Evelin Csernus
Michael Sticherling (ORCID: https://orcid.org/0000-0001-9396-3938)
Thierry Passeron (ORCID: https://orcid.org/0000-0002-0797-6570)
Nina Magnolo (ORCID: https://orcid.org/0000-0001-6802-0153)
Colleen Hamilton
Óscar M. Moreno‐Arrones (ORCID: https://orcid.org/0000-0002-4850-8394)
James V. Cassella (ORCID: https://orcid.org/0000-0003-3694-7100)
Virginie Kelly (ORCID: https://orcid.org/0000-0002-4580-4286)
Isaiah Day
Athanasios Tsianakas (ORCID: https://orcid.org/0000-0002-3430-4251)

Institutions

Southwest General Health Center (US)
Inserm (FR)
Red Deer Polytechnic (CA)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Instituto Cajal (ES)
Christoffel Blinden Mission (DE)
Red Deer Regional Hospital (CA)
Centre Hospitalier Universitaire de Nice (FR)
Institut de Chimie de Nice (FR)
University Hospital Münster (DE)
Clinique Saint-Joseph (BE)
Sun Pharma (United States) (US)
Charité - Universitätsmedizin Berlin (DE)
University of Pecs (HU)
Sun Chemical (United States) (US)
Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal: Journal of the American Academy of Dermatology
Published: 2025-11-28
DOI: https://doi.org/10.1016/j.jaad.2025.11.070
Citations: 2
Primary Topic: Hair Growth and Disorders
Type: article
Field-Weighted Citation Impact: 3.67

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

Rocco Serrao, Ulrike Blume‐Peytavi, Emma Guttman‐Yassky, Adriána Evelin Csernus et al.

Nov 28, 2025

2 citations

Journal of the American Academy of Dermatology

Hair Growth and Disorders

3.67

article

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

Rocco Serrao, Ulrike Blume‐Peytavi, Emma Guttman‐Yassky, Adriána Evelin Csernus, Michael Sticherling, Thierry Passeron, Nina Magnolo, Colleen Hamilton, Óscar M. Moreno‐Arrones, James V. Cassella, Virginie Kelly, Isaiah Day, Athanasios Tsianakas

November 28, 2025article en

2 citations

Abstract

No abstract available for this paper.

Journal of the American Academy of DermatologyVol. 94(4)

Southwest General Health Center (US), Inserm (FR), Red Deer Polytechnic (CA), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Instituto Cajal (ES), Christoffel Blinden Mission (DE), Red Deer Regional Hospital (CA), Centre Hospitalier Universitaire de Nice (FR), Institut de Chimie de Nice (FR), University Hospital Münster (DE), Clinique Saint-Joseph (BE), Sun Pharma (United States) (US), Charité - Universitätsmedizin Berlin (DE), University of Pecs (HU), Sun Chemical (United States) (US), Icahn School of Medicine at Mount Sinai (US)

Openalex Percentile: Top 6%

Hair Growth and Disorders

3.67

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.